Inpharamo will Facilitate Clinerion into Mexican Clinical Research Market

Applied Clinical Trials

Semicrol will facilitate the entry of Clinerion into Mexico through its subsidiary Inpharamo. Inpharamo’s network of contacts will serve as the gateway for the Swiss company into the country. Ian Rentsch, CEO of Clinerion, and Ricardo Márquez, Medical Director of Inpharamo, will officially launch the partnership during the second edition of the International Congress of Clinical Research, Mexico, to be held from May 16th to 18th, in Guadalajara (Jalisco.)

The partnership between Inpharamo and Clinerion is grounded on the success to-date of the alliance established by Semicrol and Clinerion in September, 2018, which has enabled the integration of the functionality of Clinerion’s Patient Network Explorer with that of Semicrol’s Fundanet CTMS (clinical trial management system.)

After a collaboration in Spain and Colombia, this partnership now expands to include Mexican hospitals and clinical research institutes in the network participating in Clinerion’s community. In support of this, Ian Rentsch, CEO of Clinerion, will speak at the International Congress of Clinical Research in Mexico, addressing the benefits of the introduction of Big Data technologies in clinical research and the impact they have on the growth of studies.

Its incorporation to the services offered by Fundanet CTMS gives users access to a network of more than 70 million patients in 17 countries.

Inpharamo and Clinerion previously jointly attended the IMC Summit, organized by the Mexican Medical Training Institute (IMC) in Mexico City, in March. There, both firms stressed the importance of modernizing clinical research processes with innovative tools and processes based on new technologies. Luis Magalhaes, representing Clinerion, gave a talk entitled "Electronic Health Records: the future of medical records and their importance in specialized medicine."

“Clinerion’s entry into the clinical research field in Mexico provides great advantages when it comes to optimizing the creation of clinical protocols, making them based on real patient data in the clinical context of interest, and enables the most proactive selection of candidates eligible for participation in the trials,” says Ricardo Márquez Oñate, Medical Director of Inpharamo. “This saves time, minimizes costs and boosts the local research market. This will make Mexico a more attractive location when it comes to the selection of trial centers by collaborating institutions or sponsors.”

“Clinerion and Semicrol’s technologies complementarily support the optimal set-up and running of clinical trials,” says Ian Rentsch, CEO of Clinerion. “Together, we bring great benefits of acceleration and efficiency to clinical research teams. We are pleased that this new partnership with Inpharamo offers another way for the two companies to work together, accelerating patient access to innovative medical treatments in Mexico.”

International Congress of Clinical Research website: www.myiccr.com